報價延遲最少15分鐘:2025/05/12 10:27 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.0547 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.51/--
|
|
企業價值
56.19M
|
| 資產負債 |
|
每股賬面淨值
0.06
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/12 10:27 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.The Company has one reportable segment relating to the research and development of its POZ platform. |